NASDAQ$KNSA
Kiniksa Pharmaceuticals Ltd · Q3 2020 earnings
Q3 2020 earnings · · Investor relations
Briefing
Kiniksa reported financial results for Q3 2020 and highlighted recent pipeline and corporate activity.
Kiniksa continues to advance its pipeline, preparing for the potential commercial launch of rilonacept in recurrent pericarditis in the first half of 2021, pending FDA approval. The mavrilimumab Phase 2 trial in giant cell arteritis achieved statistical significance in primary and secondary efficacy endpoints. All cohorts have been dosed in the Phase 1 study of KPL-404, with data expected from the first cohorts this quarter.
- Preparing for the commercial launch of rilonacept in recurrent pericarditis in the first half of 2021, if approved by the FDA.
- Mavrilimumab Phase 2 trial in giant cell arteritis achieved statistical significance in primary and secondary efficacy endpoints.
- All cohorts have been dosed in the Phase 1 study of KPL-404.
- Data from the first cohorts of KPL-404 Phase 1 study expected this quarter.
Headline financials
Revenue & EPS history
Kiniksa · Revenue · Quarterly
$214M
Revenue by segment
Kiniksa · $64.8M total across 1 segment · Q3 2023
- ARCALYST$64.8M+94.0%100.0%
Forward guidance
Kiniksa provided forward-looking statements regarding plans and timing of clinical trial data readouts, potential commercial launch of rilonacept, planned clinical trials and timing thereof, regulatory milestones and related payments, and projected timeframe for funding the current operating plan.
Tailwinds
- Plans and timing of clinical trial data readouts
- Potential commercial launch of rilonacept in recurrent pericarditis, if approved by the FDA under priority review
- Planned clinical trials and timing thereof, including a potential dose-ranging Phase 2b clinical trial of vixarelimab in prurigo nodularis
- Regulatory milestones and related payments under our License Agreement with Regeneron upon achievement of certain specified events
- Projected timeframe for funding our current operating plan with current cash, cash equivalents and short-term investments
Headwinds
- Delays or difficulty in enrollment of patients in, and activation or continuation of sites for, our clinical trials
- Potential complications in coordinating among requirements, regulations and guidelines of regulatory authorities across a number of jurisdictions for our global clinical trials
- Potential amendments to our clinical trial protocols initiated by us or required by regulatory authorities
- Delays or difficulty in completing our clinical trials, including as a result of the COVID-19 pandemic
- Potential for low accrual of events in our clinical trials
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2020
+5.3%
Avg return
Earnings day
+5.2%
Avg return
5 days after
+7.8%
Avg return
30 days after
55%
17 / 31 earnings
Positive
+45.8%
Q3 2021
Best reaction
-16.6%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +23.5% | +26.7% | +16.6% | |
| Q4 2025 | -4.7% | -6.1% | -1.3% | |
| Q3 2025 | -2.9% | -8.8% | +4.8% | |
| Q1 2025 | +20.5% | +28.8% | +26.6% | |
| Q4 2024 | +0.5% | +3.3% | +19.0% | |
| Q3 2024 | -16.6% | -18.5% | -19.1% | |
| Q2 2024 | +17.8% | +22.1% | +22.5% | |
| Q1 2024 | +4.4% | +4.6% | +12.1% | |
| Q4 2023 | +1.2% | -3.4% | -5.6% | |
| Q3 2023 | -3.4% | +3.3% | +3.1% | |
| Q2 2023 | +35.2% | +26.8% | +18.1% | |
| Q1 2023 | +24.2% | +24.7% | +29.0% | |
| Q4 2022 | -5.6% | -7.8% | -19.7% | |
| Q3 2022 | +8.6% | +21.7% | +49.3% | |
| Q2 2022 | +17.3% | +29.9% | +14.7% | |
| Q1 2022 | +5.1% | -6.8% | -18.4% | |
| Q4 2021 | -6.8% | -3.4% | -7.2% | |
| Q3 2021 | +45.8% | +41.8% | +8.8% | |
| Q2 2021 | -1.4% | -5.4% | -10.0% | |
| Q1 2021 | -9.0% | -11.4% | -19.4% | |
| Q4 2020 | -6.3% | -11.9% | -28.5% | |
| Q3 2020 | -5.9% | -7.2% | +9.6% | |
| Q2 2020 | +0.8% | -1.2% | -14.7% | |
| Q1 2020 | -7.0% | -9.2% | -0.6% | |
| Q4 2019 | -0.7% | +6.1% | -29.5% | |
| Q3 2019 | +15.7% | +24.5% | +80.8% | |
| Q2 2019 | -2.4% | -12.1% | -9.4% | |
| Q1 2019 | +8.2% | +2.6% | +6.5% | |
| Q4 2018 | -6.1% | -0.2% | +20.2% | |
| Q3 2018 | +11.9% | +5.1% | +6.2% | |
| Q2 2018 | +1.7% | +3.5% | +78.2% | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro